However, the data presented here in conjunction with clinical data on this mechanism in ALS suggests that it may not be of value to perform clinical studies with GLP-1 agonists in ALS and that resources may be more usefully focussed elsewhere. This evidence concerns the gene GCG and amyotrophic lateral sclerosis.